Vontobel Holding Ltd. Grows Stake in The Cooper Companies, Inc. (NASDAQ:COO)

Vontobel Holding Ltd. increased its holdings in The Cooper Companies, Inc. (NASDAQ:COO) by 7.8% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,208 shares of the medical device company’s stock after buying an additional 377 shares during the period. Vontobel Holding Ltd.’s holdings in Cooper Companies were worth $575,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in COO. Benjamin F. Edwards & Company Inc. lifted its position in Cooper Companies by 248.6% during the first quarter. Benjamin F. Edwards & Company Inc. now owns 244 shares of the medical device company’s stock valued at $25,000 after purchasing an additional 174 shares during the last quarter. Covestor Ltd grew its position in Cooper Companies by 305.9% in the first quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock worth $28,000 after acquiring an additional 208 shares in the last quarter. Innealta Capital LLC bought a new position in Cooper Companies in the second quarter valued at $25,000. Crewe Advisors LLC raised its position in Cooper Companies by 286.4% during the second quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock valued at $30,000 after purchasing an additional 252 shares in the last quarter. Finally, Clearstead Trust LLC bought a new stake in Cooper Companies during the first quarter worth about $36,000. Institutional investors own 24.39% of the company’s stock.

Insider Buying and Selling

In other news, COO Daniel G. Mcbride sold 114,992 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $105.48, for a total value of $12,129,356.16. Following the sale, the chief operating officer now directly owns 44,696 shares of the company’s stock, valued at $4,714,534.08. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Cooper Companies news, CFO Brian G. Andrews sold 24,788 shares of the firm’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $105.90, for a total transaction of $2,625,049.20. Following the completion of the sale, the chief financial officer now directly owns 6,614 shares in the company, valued at approximately $700,422.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Daniel G. Mcbride sold 114,992 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $105.48, for a total transaction of $12,129,356.16. Following the completion of the transaction, the chief operating officer now owns 44,696 shares in the company, valued at approximately $4,714,534.08. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 256,373 shares of company stock valued at $27,637,427 over the last quarter. Corporate insiders own 2.00% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Morgan Stanley raised their price objective on Cooper Companies from $95.00 to $104.00 and gave the company an “equal weight” rating in a report on Tuesday, September 10th. Jefferies Financial Group upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $107.00 to $115.00 in a report on Tuesday, July 16th. Wells Fargo & Company increased their target price on shares of Cooper Companies from $110.00 to $115.00 and gave the company an “overweight” rating in a report on Thursday, August 29th. Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a research report on Thursday, August 29th. Finally, Robert W. Baird upped their price target on shares of Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a research report on Thursday, August 29th. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Cooper Companies has a consensus rating of “Moderate Buy” and an average target price of $115.00.

Cooper Companies Stock Performance

Cooper Companies stock opened at $106.72 on Tuesday. The Cooper Companies, Inc. has a fifty-two week low of $75.93 and a fifty-two week high of $112.38. The stock’s 50 day simple moving average is $104.28 and its two-hundred day simple moving average is $96.42. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.18 and a current ratio of 1.99. The stock has a market cap of $21.25 billion, a price-to-earnings ratio of 62.78, a PEG ratio of 2.56 and a beta of 0.98.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Wednesday, August 28th. The medical device company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.91 by $0.05. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $997.30 million. Cooper Companies had a return on equity of 9.08% and a net margin of 9.45%. The firm’s revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.84 earnings per share. As a group, analysts expect that The Cooper Companies, Inc. will post 3.65 earnings per share for the current fiscal year.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.